



## LIST OF ON-GOING CLINICAL TRIALS AT THE MEDICAL CITY

(As of January 2024)

| Title of Clinical Trial  | STATUS   | ClinicalTrial.gov Identifier/<br>PHRR NUMBER | SITE       |
|--|----------|--|------------|
| A phase 3, randomized, multi-center, open-label, controlled study to evaluate the efficacy and safety of APL-2 in patients with Paroxysmal Nocturnal Hemoglobinuria(PNH)   | On-going | <a href="#">PHRR190808-002175</a>            | TMC PASIG  |
| A randomized, double-blind, placebo-controlled phase 3 trial of Pembrolizumab (MK-3475) versus placebo in participants with Esophageal Carcinoma receiving concurrent definitive Chemoradiotherapy (KEYNOTE 975)   | On-going | <a href="#">PHRR200210-002490</a>            | TMC ILOILO |
| A three-arm, randomized, placebo-controlled, double-blind phase 3 study to evaluate the safety and efficacy of once-daily and twice-daily dosing of a Novel Hydrocortisone Acetate 90mg suppository formulation administered with the Sephure® suppository applicator in subjects with Ulcerative Colitis of the Rectum  | On-going | <a href="#">NCT04469686</a>                  | TMC CALRK  |
| A three-arm, randomized, placebo-controlled, double-blind phase 3 study to evaluate the safety and efficacy of once-daily and twice-daily dosing of a Novel Hydrocortisone Acetate 90mg suppository formulation administered with the Sephure® suppository applicator in subjects with Ulcerative Colitis of the Rectum  | On-going | <a href="#">NCT04469686</a>                  | TMC ILOILO |
| A prospective, randomized, active treatment-controlled, evaluator-blinded (radiologist reviewer and physician evaluator) multicenter study to establish the superiority of a hyaluronan-based scaffold (Hyalofast®) with autologous bone marrow aspirate concentrate (BMAC) in the treatment of articular knee cartilage defect lesions in comparison to control (microfracture treatment) | On-going | <a href="#">NCT02659215</a>                  | TMC PASIG  |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease   | On-going | <a href="#">PHRR200903-002907</a>            | TMC CALRK  |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease   | On-going |  | TMC PASIG  |

|   |                        |  |            |
|---|------------------------|--|------------|
| A randomized, double-blind, phase 3 study of Platinum-Based Chemotherapy with or without INCMGA0012 in First-Line Metastatic Squamous and NonSquamous Non- Small Cell Lung Cancer (PODIUM-304)  | On-going               | <a href="#">NCT04205812</a>                                      | TMC PASIG  |
| An open-label, randomized phase 3 study to evaluate efficacy and safety of Pembrolizumab (MK-3475) in combination with MK-6482 and Lenvatinib (MK-7902) or MK-1308A in combination with Lenvatinib versus Pembrolizumab and Lenvatinib as firstline treatment in participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | On-going               | <a href="#">PHRR210911-003887</a>                                | TMC PASIG  |
| A phase 3 randomized, double-blind, multi-center, global study of Monalizumab or Placebo in combination with Cetuximab in patients with recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck previously treated with an Immune Checkpoint Inhibitor (INTERLINK-1)   | On-going               | <a href="#">NCT04590963</a>                                      | TMC PASIG  |
| A phase III, randomized, double-blind, placebo-controlled, multi-center study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in patients with Hepatocellular Carcinoma who are at high risk of recurrence after Curative Haptic Resection or Ablation (EMERALD-2)                                 | On-going               | <a href="#">NCT03847428</a><br><a href="#">PHRR210310-003410</a> | TMC PASIG  |
| A randomized phase 3 study evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy alone in Cisplatin-Ineligible participants with Muscle-invasive Bladder Cancer (KEYNOTE-905/EV-303)  | On-going               | <a href="#">NCT03924895</a><br><a href="#">PHRR210911-003890</a> | TMC PASIG  |
| A multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial of MW33 injection to evaluate the efficacy and safety in patients with mild or moderate COVID-19  | Active, non recruiting | <a href="#">NCT04627584</a>                                      | TMC ILOILO |
| A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolocizumab 6mg compared to panretinal photocoagulation laser in patient with proliferative diabetic retinopathy (CONDOR)  | On-going               | <a href="#">NCT04278417</a><br><a href="#">PHRR210216-003336</a> | TMC PASIG  |
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma                              | On-going               |  | TMC PASIG  |
| A multi-center, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial to evaluate the safety and efficacy of pyronaridine-artesunate (Artecom®) in COVID-19 patients  | On-going               | <a href="#">NCT04701606</a>                                      | TMC PASIG  |
| Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)   | On-going               |  | TMC PASIG  |
| A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Adjuvant Giredestrant compared with Physician's choice of Adjuvant Endocrine Monotherapy in patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer  | On-going               | <a href="#">NCT04961996</a><br><a href="#">PHRR210930-003951</a> | TMC PASIG  |

|   |          |                             |            |
|---|----------|-----------------------------|------------|
| A multi-national, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the prevention of COVID-19 in healthy adults aged 18 years and older            | On-going |                             | TMC ILOILO |
| A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older                  | On-going | <a href="#">NCT04904471</a> | TMC ILOILO |
| A global, multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy, safety and immunogenicity of Recombinant SARS- CoV-2 Fusion Protein Vaccine (V-01) in Adults aged 18 years and older                                    | On-going | <a href="#">NCT05050474</a> | TMC ILOILO |
| Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease | On-going |                             | TMC PASIG  |
| A Global, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Protective Efficacy and Safety of Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1) in Adults Aged 18 Years and Older      | On-going |                             | TMC PASIG  |
| A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine-Artesunate (Artecom®) in COVID-19 Patients  | On-going |                             | TMC ILOILO |
| A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma (DIRECTION)   | On-going |                             | TMC ILOILO |
| A Study on Efficacy, Efficacy and Immune Response Following Sequential Treatment with an Anti-sense Oligonucleotide Against Chronic Hepatitis B(CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)ide Analogue (NA) Therapy      | On-going |                             | TMC PASIG  |
| A Phase III, Open-Label, Randomized Study of Atezolizumab with Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab And Bevacizumab  | On-going |                             | TMC PASIG  |
| A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma          | On-going |                             | TMC PASIG  |



|  |          |  |            |
|--|----------|--|------------|
| A phase III, multi-center, randomised, double-blind, chronic dosing, parallel-group, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of MEDI3506 in participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with history of COPD Exacerbations (TITANIA)            | On-going |  | TMC ILOILO |
| A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)   | On-going |  | TMC ILOILO |
| A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab - Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)                             | On-going |  | TMC ILOILO |
| A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum | On-going |  | TMC ILOILO |
| A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV 304)  | On-going |  | TMC ILOILO |
| Randomized, Double blind, Placebo-Controlled, Safety Study of Investigational Nutraceutical Product 001-20 in Healthy Adult Subjects   | On-going |  | TMC ILOILO |
| A Multicenter,Randomized,Double-Blind,Placebo-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving BackgroundNonbiologic Lupus Standard of Care  | On-going |  | TMC CLARK  |
| A Multicenter,Randomized,Double-Blind,Placebo-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving BackgroundNonbiologic Lupus Standard of Care  | On-going |  | TMC ILOILO |
| A Phase II/III Randomized. Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-Cov-2   | On-going |  | TMC ILOILO |
| A Clinically-Oriented Antimicrobial Resistance Surveillance Network for Healthcare-associated infections (ACORN-HAI)   | On-going |  | TMC PASIG  |
| A Phase 3,Randomized,Placebo-Controlled, Double-Blind, Parallel-Group Program to Evaluate Efficacy and Safety of filgotinib in Adult Subjects with Active Axial Spondyloarthritis  | On-going |  | TMC CLARK  |



|  |                     |  |            |
|--|---------------------|--|------------|
| Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well2)  | On-going            |  | TMC PASIG  |
| An Online Registry of Carbapenemase Producing Gram NEgative ORganisms for Evaluating the Clinical Profile, Outcomes, Mechanisms of Resistance and Antimicrobial Stewardship Practices of Two Tertiary Level Hospitals (ORIGIN Study)   | On-going            |  | TMC PASIG  |
| A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to PlatinumBased Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations  | On-going            |  | TMC PASIG  |
| The Effect Of Silybin + Phosphatidylcholine + Multivitamins + Zinc On The Non-Invasive Parameters Of Hepatic eInjury In Adults With Metabolic Associated Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial   | On-going            |  | TMC PASIG  |
| A 2-Part Seamless Part A(Phase 2)/2Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)   | On-going            |  | TMC CLARK  |
| A Phase 3, Randomized, Observer-Blinded Study To Evaulate The Efficacy, Safety, Tolerability, And Immunogenicity Of A Modified RNA Vaccine Against Influenza Compared To Licensed Inactivated Influenza Vaccine In Healthy Adults 18 Years Of Age or Older   | On-going            |  | TMC ILOILO |
| A 2-Part Seamless Part A(Phase 2)/2Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)   | On-going            |  | TMC PASIG  |
| Open-label Phase 3 Study of MK-7684A (Colformulation of Vibostolimab with Pembrolizumab) in Combination With Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durmavulab in Participants with Unresectable Locally Advanced, Stage III NSCL   | On-going            |  | TMC PASIG  |
| A Phase III, Multicentre, Randomised, Double-blind, 17 Chronic-dosing, Parallel-group, Placebo-controlled Extension 18 Study to Evaluate the Long-term Efficacy and Safety of 19 Tozorakimab in Participants with Chronic Obstructive 20 Pulmonary Disease (COPD) with a History of Exacerbations 21 (PROSPERO)  | On-going            |  | TMC ILOILO |
| A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)   | For site activation |  | TMC PASIG  |
| Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR $\alpha$ -high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum based chemotherapy plus bevacizumab (GLOROSIA) | For site activation |  | TMC PASIG  |





|  |                     |  |            |
|--|---------------------|--|------------|
| A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)   | For site activation |  | TMC PASIG  |
| Randomized, Multicenter, Open-Label, Phase 3 Study Of Mirvetuximab Soravtansine In Combination With Bevacizumab Versus Bevacizumab Alone As Maintenance Therapy For Patients With Fr $\alpha$ -High Recurrent Platinum Sensitive Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancers Who Have Not Progressed After Second-Line Platinum Based Chemotherapy Plus Bevacizumab (GLORIOSA)                 | On-going            |  | TMC ILOILO |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (Librexia – ACS); Version 1 (28Sep2022)   | For site activation |  | TMC PASIG  |
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack (Librexia STROKE)   | For site activation |  | TMC PASIG  |
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation (LIBREXIA-AF)  | On-going IRB review |  | TMC PASIG  |
| A phase 3 randomized, double-blind study of ianalumab 10 (VAY736) versus placebo in addition to eltrombopag in 11 patients with primary immune thrombocytopenia (ITP) who 12 had an insufficient response or relapsed after first line 13 steroid treatment (VAYHIT2)  | For site activation |  | TMC PASIG  |
| A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S217622 compared with placebo in non-hospitalized participants with COVID-19   | On-going            |  | TMC CLARK  |
| A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S217622 compared with placebo in non-hospitalized participants with COVID-19   | On-going            |  | TMC ILOILO |
| A Phase 2, Open-Label Study to Assess the Safety And Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic Hepatitis C Virus (HCV) Infection   | On-going            |  | TMC CLARK  |
| Post-Marketing Observational Study On Safety And Efficacy Of Omnidenepag Isopropyl (EYBELIS) Ophthalmic Solution in Filipino Patients with Glaucoma and Ocular Hypertension  | For site activation |  | TMC PASIG  |
| A multicenter, placebo-controlled, randomized, double-blind, parallel-group comparison trial to investigate the efficacy and safety of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia   | On-going IRB review |  | TMC PASIG  |
| A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® along with Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer | On-going IRB review |  | TMC CLARK  |



|  |                     |  |            |
|--|---------------------|--|------------|
| A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® along with Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-positive Early Stage or Locally Advanced Breast Cancer | On-going IRB review |  | TMC PASIG  |
| A Phase 3 Study to Evaluate Cefepime-taniborbactam compared to Meropenem in Adults with Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)   | On-going IRB review |  | TMC ILOILO |
| An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies  | For site activation |  | TMC PASIG  |
| A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)   | On-going IRB review |  | TMC PASIG  |
| A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of the preventive COVID-19 vaccine AdCLD-CoV19-1 OMI administered as a booster to Adults aged 19 years old and above   | On-going IRB review |  | TMC ILOILO |
| A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma   | On-going IRB review |  | TMC PASIG  |
| Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Ziplertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations   | On-going IRB review |  | TMC PASIG  |
| A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations  | On-going IRB review |  | TMC PASIG  |
| A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of AP063 to Herceptin® in Subjects with HER2+ Breast Cancer   | On-going IRB review |  | TMC PASIG  |
| A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations  | On-going IRB review |  | TMC ILOILO |

